DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a research report released on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Up 10.7 %

Shares of DRRX stock opened at $0.95 on Friday. DURECT has a 12 month low of $0.49 and a 12 month high of $1.88. The company has a 50 day simple moving average of $1.10 and a two-hundred day simple moving average of $1.32. The stock has a market cap of $29.49 million, a P/E ratio of -1.56 and a beta of 1.01.

Hedge Funds Weigh In On DURECT

Large investors have recently added to or reduced their stakes in the company. Richmond Brothers Inc. raised its position in shares of DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after purchasing an additional 303,670 shares during the period. Geode Capital Management LLC increased its stake in DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares in the last quarter. Finally, International Assets Investment Management LLC raised its holdings in DURECT by 41.3% during the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after acquiring an additional 6,300 shares during the period. Hedge funds and other institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.